Cover Image

SMAC mimetics are potent latency reversal agents with single agent and combination activity ex vivo

Saved in:

Bibliographic Details
Main Authors:	R.M. Dunham (Author), G.C. Sampey (Author), D.M. Irlbeck (Author), E.P. Browne (Author), D.M. Margolis (Author)
Format:	Book
Published:	Elsevier, 2017-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

SMAC mimetics reverse HIV latency by selective activation of the non-canonical NF-κB pathway
by: G.C. Sampey, et al.
Published: (2017)

The SMAC mimetic AZD5582 reverses HIV latency as a single agent in resting primary CD4+ T cells
by: G. Sampey, et al.
Published: (2019)

Optimisation of Smac mimetics as HIV-1 latency reversing agents
by: L. Pache, et al.
Published: (2019)

Evaluation of IAP/SMAC mimetics as latency reversal agents in primary cells and cytokine induction in in vivo models predictive of cytokine release
by: B. Howell, et al.
Published: (2019)

PP 5.4 - 00184 Optimization of Smac Mimetics as HIV-1 Latency Reversing Agents
by: L. Pache, et al.
Published: (2022)

The latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed SIV-infected rhesus macaques is potentiated by CD8a cell depletion
by: M. Mavigner, et al.
Published: (2019)

Combinatorial latency reversal activity of inhibitor of apoptosis antagonists with mechanistically distinct classes of HIV latency reversal agents
by: Shane D. Falcinelli, et al.
Published: (2019)

Differential effects of HIV latency-reversing agents on T cell phenotype and function: implications for HIV cure
by: G. Clutton, et al.
Published: (2015)

Targeting apoptotic machinery as approach for anticancer therapy: Smac mimetics as anticancer agents
by: Nevine M.Y. Elsayed, et al.
Published: (2015)

Evaluating latency reactivation synergies between the bromodomain inhibitor iBET-151 and the SMAC mimetic AZD5582 in SIV-infected macaques on ART
by: A.A. Okoye, et al.
Published: (2019)

23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal
by: T.M. Mota, et al.
Published: (2016)

PP 2.9 - 00125 Impact of latency reversal agents on estrogen receptor alpha gene and protein expression
by: C. Ceriani, et al.
Published: (2022)

CD8 depletion plus signaling of the non-canonical NF-kB pathway reverses latency in SIV-infected, ART-suppressed rhesus macaques
by: M. Mavigner, et al.
Published: (2019)

Approaches to discover latency-reversing agents
Published: (2015)

Single cell analysis of HIV latency reveals diverse proviral and host cell behaviour
by: E.P. Browne, et al.
Published: (2017)

26 A novel assay to evaluate the response of patient-derived virus to latency-reversing agents ex vivo
by: H. Lu, et al.
Published: (2016)

Reactivation capacity by latency reversing agents ex vivo correlates with the size of the HIV-1 reservoir
by: Gilles Darcis, et al.
Published: (2016)

The TwistDock workflow for evaluation of bivalent Smac mimetics targeting XIAP
by: Huang Q, et al.
Published: (2019)

OP 8.2 - 00033 Interleukin-2 administration is a potent latency reversal agent in people with treated HIV infection
by: M. Freeman, et al.
Published: (2022)

CL572, a potent agonist of Toll-like receptor 2/7, as a novel latency-reversing agent
by: A. Macedo, et al.
Published: (2015)

Identification of a promising new class of latency reversing agents
by: A. Gramatica, et al.
Published: (2017)

O6 Reactivation capacity by latency reversing agents ex vivo correlates with the size of the HIV-1 reservoir
by: Gilles Darcis, et al.
Published: (2016)

Overview of the progress and prospects of SMAC mimetics in cancers: Is it a silver bullet?
by: Almuradova Elvina, et al.
Published: (2022)

Latency-reversing agents and cellular activation affect antigen processing in primary CD4 T cells
by: J. Boucau, et al.
Published: (2015)

The SMAC Mimetic APG-1387 Sensitizes Immune-Mediated Cell Apoptosis in Hepatocellular Carcinoma
by: Zide Chen, et al.
Published: (2018)

Memory CD4+ T cell subsets show differential responses to HIV latency-reversing agents
by: D.A. Kulpa, et al.
Published: (2015)

OP 2.8 - 00193 Enhancing PKC Modulator HIV Latency Reversing Agents
by: M. Marsden, et al.
Published: (2022)

Tissue-specific effects of latency-reversing agents on HIV transcriptional blocks in gut and blood
by: S. Telwatte, et al.
Published: (2019)

Novel use of alprazolam as a potential HIV-1 latency reversing agent
by: W. Elbezanti, et al.
Published: (2017)

Synergistic HIV latency reversal from an in vitro screen of epigenetic and kinase inhibitors
by: D. Irlbeck, et al.
Published: (2017)

A theoretical framework to guide clinical trial design to estimate efficacies of latency-reversing agents
by: R. Ke, et al.
Published: (2015)

O3 Heme-arginate as a latency-reversing agent for HIV-1 cure
by: Michaela Madlenakova, et al.
Published: (2017)

Defining the Effects of PKC Modulator HIV Latency-Reversing Agents on Natural Killer Cells
by: Melanie Dimapasoc, et al.
Published: (2024)

PP 1.4 - 00037 Histone decrotonylation uniquely regulates HIV-1 transcription and can be modulated to control HIV-1 latency
by: T.L. Simermeyer, et al.
Published: (2022)

Phorbol esters isolated from Croton megalobotrys reverse HIV latency ex vivo
by: I. Tietjen, et al.
Published: (2019)

Patient-derived HIV reservoirs can be stably engrafted into NSG mice and reactivated by latency-reversing agents in vivo
by: A. Ward, et al.
Published: (2017)

Induction of HIV from latency by a novel molecule
by: N.M. Archin, et al.
Published: (2015)

Mimetics of Hormetic Agents: Stress-Resistance Triggers
by: Joan Smith Sonneborn
Published: (2010)

Lymphoid tissue and blood CD4 T cells respond differently to latency-reversing agents: are we testing the right cells?
by: A. Gramatica, et al.
Published: (2015)

PP 2.13 - 00160 Enhancing Tolerability and Efficacy of Latency Reversing Agents in "Kick and Kill" HIV Cure Approaches
by: J. Moran, et al.
Published: (2022)